Vaccitech: Funding, Investors & Team (Aug 2026)

Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centers in the world. The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. The company’s protected chimpanzee adenovirus technology is the best way to generate T-cell responses and thereby generate lasting cell-mediated immunity. The assets are already in the clinic with very promising initial results. The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. This autumn, Vaccitech will begin a phase IIB efficacy study for a universal influenza vaccine in the over 65 population, and an extended phase I prostate cancer trial.

Vaccitech has raised $168M across 1 round on record. The most recent is a Series B of $168M announced in Mar 2021.

Vaccitech's most recent funding round on record is a Series B of $168M, announced in Mar 2021.

Bill Enright is listed as CEO at Vaccitech.

Vaccitech is based in Oxford, Oxfordshire, United Kingdom.

Vaccitech is in the 11-50 employee band.

Vaccitech's latest round of $168M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.